buspirone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
anxiolytics, buspirone derivatives	437	36505-84-7

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: buspirone buspin buspirone hydrochloride buspirone HCl

An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM. Molecular weight: 385.51 Formula: C21H31N5O2 CLOGP: 2.19 LIPINSKI: 0 HAC: 7 HDO: 0 TPSA: 69.64 ALOGS: -2.82 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.02 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	2.59 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	3.90 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Sept. 29, 1986	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	465.18	12.61	449	21573	145471	46518569
Anxiety	136.58	12.61	279	21743	181678	46482362
Depression	129.03	12.61	262	21760	169842	46494198
Serotonin syndrome	107.33	12.61	90	21932	24130	46639910
Suicidal ideation	99.95	12.61	128	21894	56254	46607786
Toxicity to various agents	86.32	12.61	257	21765	211509	46452531
Withdrawal syndrome	61.63	12.61	58	21964	18076	46645964
Neuroleptic malignant syndrome	48.57	12.61	41	21981	11081	46652959
Overdose	44.54	12.61	127	21895	101852	46562188
Stiff person syndrome	42.29	12.61	11	22011	174	46663866
Panic attack	39.09	12.61	48	21974	20194	46643846
Agitation	37.96	12.61	82	21940	55333	46608707
Rheumatoid arthritis	37.33	12.61	35	21987	240180	46423860
Tremor	35.85	12.61	128	21894	115511	46548529
Poisoning	35.14	12.61	38	21984	13956	46650084
Drug withdrawal syndrome	33.37	12.61	52	21970	27332	46636708
Cardio-respiratory arrest	32.65	12.61	81	21941	59788	46604252
Insomnia	31.18	12.61	157	21865	164767	46499273
Febrile neutropenia	31.02	12.61	4	22018	94623	46569417
Disturbance in attention	30.50	12.61	54	21968	31506	46632534
Weight increased	29.99	12.61	155	21867	164318	46499722
Anoxia	29.48	12.61	9	22013	260	46663780
Extrapyramidal disorder	29.00	12.61	31	21991	11237	46652803
Neutropenia	27.15	12.61	17	22005	143187	46520853
Mydriasis	27.10	12.61	29	21993	10524	46653516
Hypothermia	27.01	12.61	31	21991	12152	46651888
Plasma cell mastitis	26.90	12.61	5	22017	13	46664027
Respiratory arrest	26.62	12.61	53	21969	33763	46630277
Intentional overdose	25.58	12.61	78	21944	64866	46599174
Drug screen false positive	25.50	12.61	11	22011	866	46663174
Somnolence	24.16	12.61	141	21881	156380	46507660
Treatment failure	24.09	12.61	7	22015	93080	46570960
Thrombocytopenia	24.03	12.61	15	22007	126566	46537474
Migraine	23.85	12.61	80	21942	69946	46594094
Suicide attempt	23.48	12.61	68	21954	54968	46609072
Emotional disorder	23.43	12.61	29	21993	12295	46651745
Anaemia	23.34	12.61	54	21968	255725	46408315
Injection site mass	23.31	12.61	32	21990	15008	46649032
False positive investigation result	23.09	12.61	9	22013	547	46663493
Pre-existing condition improved	22.17	12.61	21	22001	6591	46657449
Panic disorder	21.51	12.61	14	22008	2547	46661493
Product dose omission issue	21.15	12.61	144	21878	168376	46495664
Pancytopenia	20.93	12.61	7	22015	85051	46578989
Suspected suicide	19.98	12.61	17	22005	4644	46659396
Fibromyalgia	19.52	12.61	49	21973	36414	46627626
Sleep apnoea syndrome	18.94	12.61	36	21986	22165	46641875
Anticholinergic syndrome	17.99	12.61	11	22011	1795	46662245
Exposure via ingestion	17.70	12.61	14	22008	3453	46660587
Bipolar disorder	17.17	12.61	19	22003	7158	46656882
Rhabdomyolysis	17.13	12.61	51	21971	41858	46622182
Surgery	16.81	12.61	40	21982	28745	46635295
Mania	16.70	12.61	23	21999	10823	46653217
Exposure during pregnancy	16.51	12.61	16	22006	108196	46555844
Memory impairment	16.30	12.61	76	21946	77261	46586779
Generalised anxiety disorder	16.26	12.61	10	22012	1650	46662390
Bradykinesia	16.05	12.61	14	22008	3952	46660088
Drug intolerance	16.00	12.61	28	21994	147021	46517019
Flat affect	15.80	12.61	9	22013	1289	46662751
Irritability	15.60	12.61	39	21983	28907	46635133
Infusion related reaction	15.40	12.61	15	22007	101193	46562847
Hallucination, auditory	15.35	12.61	22	22000	10734	46653306
Cerebellar infarction	15.25	12.61	10	22012	1842	46662198
Muscle rigidity	15.15	12.61	21	22001	9940	46654100
Anger	15.13	12.61	23	21999	11829	46652211
Autonomic nervous system imbalance	15.04	12.61	11	22011	2415	46661625
Behaviour disorder	14.73	12.61	10	22012	1951	46662089
Sedation	14.66	12.61	33	21989	22877	46641163
Diabetic neuropathy	14.59	12.61	13	22009	3776	46660264
General physical health deterioration	14.55	12.61	20	22002	115749	46548291
Therapy cessation	14.48	12.61	36	21986	26593	46637447
Akathisia	14.42	12.61	18	22004	7696	46656344
Nightmare	14.26	12.61	27	21995	16571	46647469
Depressed mood	14.04	12.61	41	21981	33278	46630762
Narcolepsy	14.01	12.61	8	22014	1151	46662889
Mental disorder	14.01	12.61	32	21990	22393	46641647
Renal impairment	13.85	12.61	9	22013	74363	46589677
Alcoholism	13.62	12.61	10	22012	2208	46661832
Product substitution issue	13.60	12.61	25	21997	15006	46649034
Alcohol withdrawal syndrome	13.52	12.61	7	22015	830	46663210
Hyperhidrosis	13.47	12.61	80	21942	89228	46574812
Cognitive disorder	13.32	12.61	43	21979	36840	46627200
Delusion	13.29	12.61	21	22001	11167	46652873
Illness	13.23	12.61	22	22000	12202	46651838
Macroglossia	13.11	12.61	6	22016	544	46663496
Accidental death	12.94	12.61	9	22013	1826	46662214
Cardiac death	12.77	12.61	6	22016	577	46663463
Lower respiratory tract infection	12.76	12.61	5	22017	55084	46608956
Psychotic disorder	12.74	12.61	31	21991	22590	46641450
Appetite disorder	12.72	12.61	14	22008	5240	46658800

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	129.65	15.98	147	8005	99345	29844981
Anxiety	115.70	15.98	132	8020	89739	29854587
Serotonin syndrome	85.81	15.98	56	8096	17835	29926491
Suicidal ideation	71.63	15.98	67	8085	36047	29908279
Agitation	55.64	15.98	71	8081	54002	29890324
Electrocardiogram QRS complex prolonged	40.93	15.98	21	8131	4256	29940070
Depression	37.92	15.98	79	8073	90358	29853968
Sedation	37.58	15.98	33	8119	16340	29927986
Insomnia	35.08	15.98	78	8074	93258	29851068
Tremor	34.15	15.98	68	8084	75295	29869031
Irritability	33.23	15.98	36	8116	23014	29921312
Muscle necrosis	32.59	15.98	11	8141	773	29943553
Lens dislocation	28.65	15.98	5	8147	17	29944309
Withdrawal syndrome	28.51	15.98	24	8128	11226	29933100
Akathisia	27.11	15.98	18	8134	5886	29938440
Toxicity to various agents	26.72	15.98	107	8045	177076	29767250
Anger	26.70	15.98	23	8129	11097	29933229
Neuroleptic malignant syndrome	26.24	15.98	27	8125	16268	29928058
Product dose omission issue	25.26	15.98	68	8084	91563	29852763
Nightmare	25.06	15.98	23	8129	12053	29932273
Hypertensive urgency	23.40	15.98	5	8147	58	29944268
Fear of weight gain	22.61	15.98	4	8148	15	29944311
Feeling abnormal	19.70	15.98	46	8106	56710	29887616
Electrocardiogram QT prolonged	19.51	15.98	35	8117	35800	29908526
Seizure	19.48	15.98	65	8087	98410	29845916
Orthostatic tremor	18.33	15.98	3	8149	6	29944320
Atrioventricular block second degree	17.97	15.98	11	8141	3129	29941197
Gynaecomastia	17.51	15.98	16	8136	8335	29935991
Pneumonia	17.46	15.98	41	8111	334265	29610061
Drug withdrawal syndrome	17.25	15.98	24	8128	19785	29924541
Panic attack	16.98	15.98	16	8136	8665	29935661
Feeling of despair	16.42	15.98	7	8145	933	29943393
Dysphoria	16.20	15.98	9	8143	2139	29942187
Bipolar disorder	16.11	15.98	11	8141	3765	29940561

Pharmacologic Action:

Source	Code	Description
ATC	N05BE01	NERVOUS SYSTEM PSYCHOLEPTICS ANXIOLYTICS Azaspirodecanedione derivatives
CHEBI has role	CHEBI:35474	minor tranquilisers
CHEBI has role	CHEBI:35717	sedatives
CHEBI has role	CHEBI:35941	serotonergic agonists
CHEBI has role	CHEBI:76779	prolyl oligopeptidase (ec 3.4.21.26) inhibitor
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D018490	Serotonin Agents
MeSH PA	D017366	Serotonin Receptor Agonists
MeSH PA	D014149	Tranquilizing Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Generalized anxiety disorder	indication	21897009	DOID:14320
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.51	Basic
pKa2	2.23	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN	PARTIAL AGONIST	EC50	7.25		WOMBAT-PK	CHEMBL
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	7		WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	6.28		DRUG MATRIX
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	7.68		WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	6.44		WOMBAT-PK
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.04		WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	6.41		WOMBAT-PK
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.60		WOMBAT-PK
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		Ki	5.13		WOMBAT-PK
Solute carrier family 22 member 2	Transporter	O15244	S22A2_HUMAN		IC50	4.92		CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.18		CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.40		CHEMBL
Multidrug and toxin extrusion protein 2	Transporter	Q86VL8	S47A2_HUMAN		IC50	4.34		CHEMBL
Multidrug and toxin extrusion protein 1	Transporter	Q96FL8	S47A1_HUMAN		IC50	5.77		CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.32		WOMBAT-PK
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		IC50	5.47		DRUG MATRIX
D(1A) dopamine receptor	GPCR		DRD1_BOVIN		Ki	5.21		CHEMBL
Adrenergic receptor alpha-1	GPCR		ADA1A_RAT ADA1B_RAT ADA1D_RAT		Ki	6.86		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_BOVIN		Ki	7.36		CHEMBL
Serotonin 2 (5-HT2) receptor	GPCR		5HT2A_RAT 5HT2B_RAT 5HT2C_RAT		Ki	6.76		CHEMBL
Dopamine receptor	GPCR		DRD1_RAT DRD2_RAT DRD3_RAT DRD4_RAT DRD5_RAT		IC50	6.92		CHEMBL
Adrenergic receptor alpha-2	GPCR		ADA2A_RAT ADA2B_RAT ADA2C_RAT		IC50	5		CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_BOVIN		IC50	4.80		CHEMBL
Alpha-2A adrenergic receptor	GPCR		ADA2A_BOVIN		IC50	5		CHEMBL
Serotonin 1 (5-HT1) receptor	GPCR		5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT		IC50	7.02		CHEMBL
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	7.77		CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		Ki	8.42		CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor		SGMR1_RAT		Ki	7.32		CHEMBL
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_BOVIN		Ki	6.75		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	6.92		CHEMBL
5-hydroxytryptamine receptor 2C	GPCR		5HT2C_RAT		IC50	6		CHEMBL
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT		Ki	6.32		CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_MOUSE	ANTAGONIST	Ki	6.40		IUPHAR
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT	AGONIST	Ki	6.40		IUPHAR

External reference:

ID	Source
4019646	VUID
N0000147739	NUI
D00702	KEGG_DRUG
33386-08-2	SECONDARY_CAS_RN
4018813	VANDF
4019646	VANDF
C0006462	UMLSCUI
CHEBI:3223	CHEBI
CHEMBL49	ChEMBL_ID
CHEMBL1200399	ChEMBL_ID
DB00490	DRUGBANK_ID
D002065	MESH_DESCRIPTOR_UI
3456	INN_ID
2477	PUBCHEM_CID
36	IUPHAR_LIGAND_ID
TK65WKS8HL	UNII
1827	RXNORM
37673	MMSL
4308	MMSL
d00182	MMSL
001468	NDDF
004586	NDDF
387523009	SNOMEDCT_US
419484002	SNOMEDCT_US
91452003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0053	TABLET	5 mg	ORAL	ANDA	29 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0054	TABLET	10 mg	ORAL	ANDA	29 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1003	TABLET	15 mg	ORAL	ANDA	29 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5200	TABLET	30 mg	ORAL	ANDA	29 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1140	TABLET	5 mg	ORAL	ANDA	27 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1145	TABLET	7.50 mg	ORAL	ANDA	27 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1150	TABLET	10 mg	ORAL	ANDA	27 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1165	TABLET	15 mg	ORAL	ANDA	27 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1175	TABLET	30 mg	ORAL	ANDA	27 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-4575	TABLET	10 mg	ORAL	ANDA	29 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-4595	TABLET	5 mg	ORAL	ANDA	29 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-4596	TABLET	15 mg	ORAL	ANDA	29 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7633	TABLET	5 mg	ORAL	ANDA	30 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7634	TABLET	10 mg	ORAL	ANDA	30 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7635	TABLET	15 mg	ORAL	ANDA	30 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7689	TABLET	15 mg	ORAL	ANDA	30 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7714	TABLET	5 mg	ORAL	ANDA	30 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7718	TABLET	10 mg	ORAL	ANDA	30 sections
Buspirone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6899	TABLET	15 mg	ORAL	ANDA	22 sections
Buspirone HCl	HUMAN PRESCRIPTION DRUG LABEL	1	10544-176	TABLET	10 mg	ORAL	ANDA	27 sections
BUSPIRONE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-375	TABLET	30 mg	ORAL	ANDA	27 sections
BUSPIRONE HCl	HUMAN PRESCRIPTION DRUG LABEL	1	16590-579	TABLET	15 mg	ORAL	ANDA	27 sections
BUSPIRONE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-600	TABLET	10 mg	ORAL	ANDA	13 sections
BUSPIRONE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-727	TABLET	7.50 mg	ORAL	ANDA	26 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-200	TABLET	5 mg	ORAL	ANDA	29 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-201	TABLET	7.50 mg	ORAL	ANDA	29 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-202	TABLET	10 mg	ORAL	ANDA	29 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-203	TABLET	15 mg	ORAL	ANDA	29 sections
Buspirone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-289	TABLET	30 mg	ORAL	ANDA	29 sections
Buspirone HCl	HUMAN PRESCRIPTION DRUG LABEL	1	21695-172	TABLET	15 mg	ORAL	ANDA	27 sections